Hepatitis C in Chronic Kidney Disease After the DAA Revolution: Clinical Decisions, Transplantation, and Implementation Challenges. (PubMed, J Clin Med) - Sep 16, 2026 - "Present evidence supports using the recommended DAA regimens without renal dose adjustment, while ribavirin needs dose modification when kidney function is reduced and can result in hemolytic anemia. Antiviral therapy is the first-line treatment for HCV-associated glomerular disease, while rituximab-based immunosuppression is largely reserved for severe, rapidly progressive, or persistent cryoglobulinemic vasculitis. Future progress will depend less on proving antiviral efficacy and more on closing the gaps between screening, confirmatory testing, starting treatment, transplantation pathways, and long-term follow-up, gaps that stem from inequities in diagnostic infrastructure, drug reimbursement, and healthcare-system organization as much as from any remaining biomedical uncertainty."
Journal • Review • Chronic Kidney Disease • Complement-mediated Rare Disorders • Fibrosis • Glomerulonephritis • Hematological Disorders • Hepatitis C • Immunology • Infectious Disease • Inflammation • Lupus Nephritis • Nephrology • Renal Disease • Transplantation • Vasculitis
|
|
Ali Someili; Erwa Elmakki; Mohammed Abdulrasak; Mostafa Mohrag
|